Biomarker ID | 2003 |
PMID | 22589488 |
Year | 2012 |
Biomarker | Methylation status of BCL11B |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Methylated in systemic Recurrence |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Systemic recurrence vs. local recurrence |
Type of Biomarker | Prognostic |
Cohort | Systemic recurrence (n = 36) versus local recurrence (n = 44) |
Senstivity | Training:82.6 (61.2–95.0); validation: 75.2 (50.9–91.3) |
Specificity | Training: 80.5 (63.9–91.8); validation: 60.0 (36.0–80.8) |
AUC | Training: 0.80; validation: 0.74 |
Accuracy | NA |
Level Of Significance | <0.0001 |
Method Used | Pyrosequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | BCL11B |